SPONSOR
Celyad Oncology SA
Total Trials
3
Recruiting
3
Phases
Phase 1
Conditions studied: Unresectable Metastatic Colorectal CancerAcute Myeloid LeukemiaMyelodysplastic Syndrome
NCT03692429 Phase 1
Recruiting
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
Unresectable Metastatic Colorectal Cancer
NCT04991948 Phase 1
Recruiting
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
Unresectable Metastatic Colorectal Cancer
NCT04167696 Phase 1
Recruiting
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
Acute Myeloid Leukemia
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology